A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

Launched by ZHEJIANG WENDA MEDICAL TECHNOLOGY CO., LTD. · Mar 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called WD-890 for people with moderate to severe plaque psoriasis, a common skin condition that causes red, scaly patches. The main goal is to see how effective different doses of WD-890 are after 16 weeks of treatment. The trial is currently looking for participants aged 18 to 70 who have been diagnosed with plaque psoriasis for at least six months and have a significant amount of skin affected by the condition.

To qualify for the study, participants need to have certain levels of severity in their psoriasis, as measured by specific scoring systems. However, individuals with other types of psoriasis or certain health conditions, like uncontrolled high blood pressure or serious heart issues, will not be eligible to join. If you decide to participate, you can expect regular check-ups to monitor your skin condition and overall health throughout the trial. This study aims to find out if WD-890 can help improve the symptoms of plaque psoriasis, which could lead to better treatment options for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent.
• • Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.
• • ≥10% of BSA involvement at screening visit and randomization;
• • Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization
• Exclusion Criteria:
• • Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)
• • Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted
• • Class III or IV congestive heart failure by New York Heart Association Criteria
• • Participant with a history of chronic bacterial infections (e.g., chronic pyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).